Name (Synonyms) | Correlation | |
---|---|---|
drug1194 | Indomethacin Wiki | 1.00 |
drug1613 | No intervention Wiki | 0.24 |
drug1086 | Hydroxychloroquine Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention and control measures, as well as supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. An array of drugs approved for other indications as well as several investigational drugs are being studied in several hundred clinical trials that are underway across the globe; however, currently there are no clinical trials available to patients in Arizona. This study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2
Description: measured by time (days) required from initiation of treatment to improvement of clinical status from mild to symptom free
Measure: Improvement of clinical status Time: up to 28 daysDescription: the time of normalization of fever as measured by daily temperature ( - ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic)
Measure: Time of clinical recovery of fever Time: up to 15 daysDescription: the time of alleviation of cough as measured by self reported visual analog scale (VAS) cough scale. 1=no cough, 2-3=cough sometimes, 4-6=have a cough but can still do things, 7-8=persistent cough, prevents from doing things, 9-10=cough presents a great deal of discomfort
Measure: Time of clinical recovery of cough Time: up to 28 daysDescription: to determine the safety of these therapies in combination
Measure: Safety as determined by changes in QTC intervals measured by ECG Time: up to 15 daysDescription: to assess the presence or absence of side effects and whether they are tolerable
Measure: Safety as determined by presence of side effects Time: up to 15 daysDescription: improvement in Wisconsin Upper Respiratory Symptom Survey (WURSS-44) 0 to 7 scale, with 0 = Do not have, 1 = Very mild, 3 = Mild, 5 = Moderate, 7 = Severe
Measure: Time to improvement Time: up to 28 days